Naproxen Bp Milpharm (Naproxen Bp)

Naproxen works by reversibly blocking the cyclooxygenase‑1 and cyclo‑oxygenase‑2 enzymes, which are essential for prostaglandin production. Lower prostaglandin levels reduce inflammation, diminish pain signaling, and help lower elevated body temperature.

The appropriate dose of Naproxen Bp Milpharm is determined by the prescribing clinician based on the patient’s condition, severity of symptoms, and individual risk factors. Dosage regimens are not standardized and should follow the prescriber’s instructions.

Safety of naproxen in pregnancy and lactation is not fully established. It should only be used if the potential benefit outweighs the risk, and under the guidance of a qualified healthcare professional. Breastfeeding mothers should discuss alternatives with their physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both naproxen and ibuprofen belong to the NSAID class and share similar mechanisms of COX inhibition. Naproxen generally has a longer half‑life, allowing less frequent dosing, while ibuprofen may have a slightly faster onset. Choice depends on clinical judgment, patient tolerance and specific therapeutic goals.

Store Naproxen Bp Milpharm at room temperature, below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains tightly closed to maintain stability.

Naproxen Bp Milpharm is taken orally, usually with a full glass of water. It can be taken with or without food, but taking it with food or milk may help reduce gastrointestinal discomfort.

Serious risks include gastrointestinal bleeding or ulcer perforation, cardiovascular events such as heart attack or stroke, acute kidney injury, severe skin reactions, and liver toxicity. Patients should be monitored for these events, especially if they have pre‑existing risk factors.

Individuals with known hypersensitivity to naproxen or other NSAIDs, those with active gastrointestinal ulceration or bleeding, severe heart failure, uncontrolled hypertension, or significant renal or hepatic impairment should avoid using Naproxen Bp Milpharm unless directed by a physician.